Response to Pneumococcal Polysaccharide Vaccination in Newly Diagnosed HIV-Positive Individuals

BACKGROUND: Newly diagnosed HIV-positive individuals are 35 to 100-fold more susceptible to Streptococcus pneumoniae infection compared to non-infected individuals. Therefore, the 23-valent pneumococcal polysaccharide vaccine (PPV23) has previously been recommended, though efficacy and effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Leggat, David J, Iyer, Anita S, Ohtola, Jennifer A, Kommoori, Sneha, Duggan, Joan M, Georgescu, Claudiu A, Khuder, Sadik A, Khaskhely, Noor M, Westerink, MA Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405239/
https://www.ncbi.nlm.nih.gov/pubmed/25908995
http://dx.doi.org/10.4172/2155-6113.1000419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405239/
https://www.ncbi.nlm.nih.gov/pubmed/25908995
http://dx.doi.org/10.4172/2155-6113.1000419

Ejemplares similares